FDA approves first-in-class SYK inhibitor

被引：0

|

作者：

Asher Mullard

机构：

来源：

Nature Reviews Drug Discovery | 2018年 / 17卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：385 / 385

相关论文

共 50 条

[31] FDA approves first PI3K inhibitor
Nature Reviews Drug Discovery, 2014, 13 (9) : 644 - 645
[32] FDA approves first PI3K inhibitor
不详
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (09) : 644 - 645
[33] Romosozumab: A first-in-class scierostin inhibitor for osteoprosis
Prather, Caitlin
Adams, Erin
Zentgraf, Whitney
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (23) : 1949 - 1956
[34] FDA approves first EGFR exon 20 targeted kinase inhibitor
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (11) : 806 - 806
[35] FDA APPROVES FIRST BIOSIMILAR
Erickson, Britt
CHEMICAL & ENGINEERING NEWS, 2015, 93 (11) : 4 - 4
[36] FDA approves first EGFR exon 20 targeted kinase inhibitor
Asher Mullard
Nature Reviews Drug Discovery, 2021, 20 : 806 - 806
[37] FDA approves first bispecific
Asher Mullard
Nature Reviews Drug Discovery, 2015, 14 : 7 - 7
[38] FDA approves first bispecific
不详
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (01) : 7 - 7
[39] Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure
Fala, Loretta
AMERICAN HEALTH AND DRUG BENEFITS, 2015, 8 (06):
[40] Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor
Hubbard, Joleen M.
Grothey, Axel
DRUGS, 2017, 77 (10) : 1091 - 1103

← 1 2 3 4 5 →